Hyperkalemia

Spironolactone With Patiromer in the Treatment of Resistant Hypertension in Chronic Kidney Disease
NCT03071263 | PHASE 2 | INTERVENTIONAL

The purpose of this study is to determine if patiromer treatment in chronic kidney disease (CKD) subjects receiving spironolactone for the treatment of resistant hypertension will result in more persistent use of spironolactone through prevention of hyperkalemia and lead to improved blood pressure control compared with treatment with spironolactone alone (placebo).

Trial Information
40 Sites
295 Participants
Recruiting
18 Years to 65 Years

If interested, contact clinicaltrials@cslbehring.com for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

SUBMIT
Investigator Site
Hollywood,Florida,United States,33021
Investigator Site
Miami Lakes,Florida,United States,33014
Investigator Site
Chicago,Illinois,United States,60611
Investigator Site
Sofia,Bulgaria,1612
Investiagor Site
Zagreb,Croatia,10000
Investigator Site
Zagreb,Croatia,10000
Investigator Site
Zagreb,Croatia,10000
Investigator Site
Zagreb,Croatia,10000
Investigator Site
Tbilisi,Georgia,0102
Investigator Site
Tbilisi,Georgia,0112
Investigator Site
Tbilisi,Georgia,0144
Investigator Site
Tbilisi,Georgia,0159
Investigator Site
Tbilisi,Georgia,0159
Investigator Site
Tbilisi,Georgia,0159
Investigator Site
Tbilisi,Georgia,0159
Investigator Site
Tbilisi,Georgia,0159
Investigator Site
Tbilisi,Georgia,0159
Investigator Site
Tbilisi,Georgia,0159
Investigator Site
Tbilisi,Georgia,0159
Investigator Site
Tbilisi,Georgia,0186
Investigator Site
Gottingen,Germany,37075
Investigator Site
Balatonfured,Hungary,H-8230
Investigator Site
Budapest,Hungary,H-1097
Investigator Site
Debrecen,Hungary,4032
Investigator Site
Hatvan,Hungary,H-3000
Investigator Site
Kistarcsa,Hungary,H-2143
Investigator Site
Miskolc,Hungary,H-3529
Investigator Site
Miskolc,Hungary,H-3530
Investigator Site
Mosonmagyarovar,Hungary,H-9200
Investigator Site
Johannesburg,South Africa
Investigator Site
Khar'kov,Ukraine,61006
Investiagor Site
Kharkiv,Ukraine,61002
Investigator Site
Kharkiv,Ukraine,61039
Investigator Site
Kharkiv,Ukraine,61103
Investigator Site
Kiev,Ukraine,03680
Investigator Site
Kiev,Ukraine,04114
Investigator Site
Zaporizhzhia,Ukraine,69001
Investigator Site
Zaporizhzhia,Ukraine,69118
Investigator Site
Leicester,United Kingdom,LE54QF
Investigator Site
London,United Kingdom,Se59RS

Study Eligibility Criteria

Additional Studies

Additional studies can be found at ClinicalTrials.gov